Small Cap Feast
Small Cap Feast – 01 May 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 897
Total number of AIM Companies trading: 826*
* As at 25 April 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 25 April 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 161*
Total number of Standard List Companies trading: 141*
* As at 25 April 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Finablr plc— global platform which provides Cross-Border Payments and Consumer Solutions, Consumer Foreign Exchange Solutions and B2B and Payment Technology Solutions to consumers and businesses in the large and growing payments and foreign exchange market is looking to list on the Main Market plans to raise $200m, expected May 2019
Main Market (Standard)
IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019
SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.
Distribution Finance Capital Holdings plc — specialist lender which builds relationships with manufacturers and then provides working capital solutions up and down their supply chains to drive their growth is looking to join AIM. No raise, secondary offering of £19.8m at 90p, expected market cap of £95.98m. Expected 09 May 2019.
Alumasc Group plc, the premium building products, systems and solutions group, has announced its intention to move from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019
Arbuthnot Banking Group plc, primarily involved in banking and financial services including commercial banking, private banking, wealth planning and investment management, is looking to joining the NEX Exchange Growth Market. Expected 17 May 2019
Nichols (NICL.L) 1,782p £657.73m
Nichols plc, the soft drinks group, will make the following statement at the Group’s AGM
Total Group revenue for the first quarter of 2019 was £30.6m (2018: £27.8m).
International sales growth in Q1 has been strong with revenue totalling £6.5m, which is 24.4% ahead of the prior year period (Q1 2018: £5.2m). This performance was anticipated as the Middle East returned to growth following the relatively softer comparatives in Q1 2018.
In the UK, first quarter sales totalled £24.1m which was 6.8% ahead of the prior year period (Q1 2018: £22.5m).
Whilst we believe that trading conditions will remain challenging in 2019, we anticipate that full year earnings will be in line with market expectations.
Hummingbird Resources (HUM.L) 16.75p £58.36m
Hummingbird Resources, announced an update on the 25-year Mineral Development Agreement (MDA) with the Government of Liberia (GoL) over a land package of approximately 2,000km2, which includes the Company’s 4.2Moz Dugbe Gold Project.
The MDA has now been signed with the Government of Libera, attested to by the Minister of Justice, ratified by the National Legislature of the Republic of Liberia, approved into law by the President of the Republic of Liberia and published in handbills signifying the completion of all necessary steps for the MDA to become immediately effective. This will provide the necessary long-term stability and framework for the next steps at Dugbe. The Dugbe MDA is the first gold MDA to be negotiated with the Government of Liberia following a discovery in over 10 years and represents a huge milestone for both the Government and the Company.
TP Group (TPG.L) 6.7p £48.9m
TP Group, the specialist services and engineering group, announced the acquisition of the entire issued share capital of Sapienza Consulting Holding BV. for an initial cash consideration of €10m and €1.5m by way of the issue of 20,612,865 new ordinary shares of 1p each in the Company. In addition, a maximum of €2m may also be payable in cash on delivery by the vendors of certain transition activities within two years following completion of the acquisition.
The directors of TP Group expect that the acquisition of Sapienza will be earnings accretive to the Group for the year ending 31 Dec 20191 and significantly earnings accretive for the year ending 31 Dec 2020. The cash element of the consideration will be funded from existing cash resources. The deal is to be completed on a debt-free, cash-free, normalised working capital basis, with a two-year lock-in on the Consideration Shares.
Tlou Energy (TLOU.L) 7p £26.1m
Tlou Energy announced that Botswana’s Department of Environmental Affairs has approved the Environmental Impact Statement (“EIS”) for up to 20MW Coal Bed Methane (“CBM”) Power Generation, a 66kV Transmission Line to Serowe and a Solar Farm up to 20MW.
Downstream EIS approval is a major achievement as it is the final environmental authorisation required to move the Lesedi CBM Project through to commercialisation;
The EIS is for all the specified project activities in the Company’s application and is valid for 30 years;
The approval provides the Company the flexibility to rapidly expand to 20MW of CBM generation and provides additional approval for a Solar Farm of up to 20MW;
Upstream EIS approval is already in place.
Osirium Technologies (OSI) 95p £12.88m
Osirium Technologies, a leading vendor of cloud-based cybersecurity software, announced the immediate availability of Opus, its secure IT Process Automation solution.
Opus builds on Osirium’s proven success in Privileged Task Automation, providing a highly-flexible platform for automating essential IT processes. The product has been designed to address currently unresolved challenges of overloaded IT teams, growing backlogs of customer requests and increasing needs to improve security.
Kromek (KMK.L) 25.8p £87.8m
Kromek, a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announced that it has received an order expansion under its five-year contract in the security screening market that was awarded and announced on 22 Feb 2017. This order expansion has increased the total value of the contract to a minimum of $5.8m over the period, with the additional $2.7m expected to be recognised over the next 24 months.
Kromek commenced delivery under the contract in 2017 with orders as expected for the first two years. For years three and four, the customer has increased its order quantities resulting in the contract now having a minimum value of $5.8m, compared with the original $3.1m minimum, over the five-year period.
Augean (AUG.L) 105p £95.6m
Augean, one of the UK’s leading specialist waste management businesses provides the following trading update. Due to stronger Group trading performance in the first quarter, the Group’s profit for the year to 31 Dec 2019 is expected to be materially ahead of market expectations. Results have benefitted from higher landfill volumes across most waste types, increased radioactive waste profit and strong performance of both the treatment and North Sea businesses.
The Group expects to announce its Interim Results for the six months ended 30 June 2019 on 17 July.
First Property Group (FPO.L) 50.50p £52.8m
First Property Group, the award winning property fund manager and investor with operations in the UK and Central Europe, reported that its PBT for the year to 31 March is likely to significantly exceed market expectations of £6.8m.
Funds under management at the year-end amounted to £705m (2018: £626m), an increase of 12.6% from the prior year. Of this some £611m was held for clients (2018: £454m), an increase of 34.6% from the prior year.
Forbidden Technologies (FBT.L) 6.25p £18.47m
Forbidden Technologies, the developer and seller of the market-leading cloud video platform, Blackbird, announced that Deltatre has signed an agreement to extend its use of Blackbird for a further 12 months.
Deltatre is a leading global provider of digital and broadcast services within the sports sector. The company works with rights owners and rights holders to grow the popularity of sports by giving fans even more exciting and immersive experiences. Achieving this enhances the brands of sports leagues, federations, franchises, TV networks and other content providers.
Deltatre uses Blackbird for the fast turn-around of long and short-form game highlights and clips for a wide range of sports including rugby, cycling and athletics. Once clipped, edited and enriched, game highlights can be distributed to social, mobile, web, over-the-top (“OTT”) and on-demand platforms simply and quickly. Deltatre runs Blackbird on the Microsoft Azure cloud platform with users able to rapidly edit, manage and distribute content collaboratively from North America and Europe, all through a browser using limited bandwidth.
Motif Bio (MTFB.L) 10.4p £29.7m
Motif Bio, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar’s patented LAMELLASOME™ technology. Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar’s LAMELLASOME™ candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.
The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.